The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in Pseudomonas aeruginosa Isolates in Cystic Fibrosis

References

1. 1.↵
   Cystic Fibrosis Foundation. About cystic fibrosis. Available at: https://www.cff.org/What-is-CF/About-Cystic-Fibrosis. Accessed February 17, 2021.
2. 2.↵
   1. Mogayzel PJ Jr.,
   2. Naureckas ET,
   3. Robinson KA,
   4. Mueller G,
   5. Hadjiliadis D,
   6. Hoag JB,
   7. et al

   . Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-689.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Smith S,
   2. Rowbotham NJ,
   3. Regan KH

   . Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2018;3:CD001021. doi: 10.1002/14651858.CD001021.pub3.

   OpenUrl
4. 4.↵
   1. Castellani C,
   2. Duff AJA,
   3. Bell SC,
   4. Heijerman HGM,
   5. Munck A,
   6. Ratjen F,
   7. et al

   . ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018;17(2):153-178.

   OpenUrlPubMed
5. 5.↵
   1. Daniels T,
   2. Mills N,
   3. Whitaker P

   . Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev 2013;4:CD007639. doi: 10.1002/14651858.CD007639.pub2.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Westerman EM,
   2. Boer AH,
   3. Touw DJ,
   4. Brun PP,
   5. Roldaan AC,
   6. Frijlink HW,
   7. et al

   . Aerosolization of tobramycin (TOBI) with the Pari LC Plus reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. J Aerosol Med Pulm Drug Deliv 2008;21(3):269-280.

   OpenUrlPubMed
7. 7.↵
   Electronic Medicines Compendium. Tobramycin. 2020. Available at: https://www.medicines.org.uk/emc/search?q=tobramycin. Accessed September 3, 2020.
8. 8.↵
   1. Daniels T,
   2. Goodacre L,
   3. Sutton C,
   4. Pollard K,
   5. Conway S,
   6. Peckham D

   . Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140(2):425-432.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Conway SP,
   2. Pond MN,
   3. Hamnett T,
   4. Watson A

   . Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51(1):29-33.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Vecellio L,
    2. Abdelrahim ME,
    3. Montharu J,
    4. Galle J,
    5. Diot P,
    6. Dubus JC

    . Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. J Cyst Fibros 2011;10(2):86-92.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Clavel A,
    2. Boulaméry A,
    3. Bosdure E,
    4. Luc C,
    5. Lanteaume A,
    6. Gorincour G,
    7. et al

    . Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis. J Cyst Fibros 2007;6(2):137-143.

    OpenUrlCrossRefPubMed
12. 12.
    1. Eisenberg J,
    2. Pepe M,
    3. Pepe M,
    4. Vasiliev M,
    5. Montgomery AB,
    6. Smith AL,
    7. Ramsey BW

    . A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111(4):955-962.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.
    1. Geller DE,
    2. Rosenfeld M,
    3. Waltz DA,
    4. Wilmott RW

    , AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003;123(1):28-36.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Hubert D,
    2. Leroy S,
    3. Nove-Josserand R,
    4. Murris-Espin M,
    5. Mely L,
    6. Dominique S,
    7. et al

    . Pharmacokinetics and safety of tobramycin administered by the Pari eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009;8(5):332-337.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Lenney W,
    2. Edenborough F,
    3. Kho P,
    4. Kovarik JM

    . Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros 2011;10(1):9-14.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Ramsey BW,
    2. Dorkin HL,
    3. Eisenberg JD,
    4. Gibson RL,
    5. Harwood IR,
    6. Kravitz RM,
    7. et al

    . Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24):1740-1746.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), 40th edition. 2020. Available at: https://www.fda.gov/media/71474/download. Accessed September 3, 2020.
18. 18.↵
    Cystic Fibrosis Foundation Patient Registry 2018 Annual Data Report. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf. Accessed September 3, 2020.
19. 19.↵
    1. Lester MK,
    2. Eidson DM

    , Cystic Fibrosis Foundation Nebulizer and Compressor Task Force. Acquisition and use of nebulizer and compressor equipment in cystic fibrosis: a national survey of patients and providers. Ped Pulmonol 2019;54(S2):S478.

    OpenUrl
20. 20.↵
    1. Kidd TJ,
    2. Canton R,
    3. Ekkelenkamp M,
    4. Johansen HK,
    5. Gilligan P,
    6. LiPuma JJ,
    7. et al

    . Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros 2018;17(6):696-704.

    OpenUrlCrossRef
21. 21.↵
    1. McCarthy K

    . Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy. Semin Respir Crit Care Med 2015;36(1):44-55.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Gramegna A,
    2. Moore JE,
    3. McCaughan J,
    4. Millar BC,
    5. Ewing J,
    6. Elborn JS,
    7. et al

    . Increasing burden of antimicrobial resistance in Pseudomonas aeruginosa from adult patients with cystic fibrosis (CF) in Northern Ireland: then and now. Ulster Med J 2018;87(2):129-130.

    OpenUrl
23. 23.↵
    1. Smyth AR,
    2. Bell SC,
    3. Bojcin S,
    4. Bryon M,
    5. Duff A,
    6. Flume P,
    7. et al

    . European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 2014;13(Suppl 1):S23-S42.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Döring G,
    2. Flume P,
    3. Heijerman H,
    4. Elborn JS

    , Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11(6):461-479.

    OpenUrlCrossRefPubMed
25. 25.
    1. Flume PA,
    2. VanDevanter DR

    . Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev 2015;85:1-6.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Mustafa MH,
    2. Chalhoub H,
    3. Denis O,
    4. Deplano A,
    5. Vergison A,
    6. Rodriguez-Villalobos H,
    7. et al

    . Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Northern Europe. Antimicrob Agents Chemother 2016;60(11):6735-6741.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Raymond B

    . Five rules for resistance management in the antibiotic apocalypse, a road map for integrated microbial management. Evol Appl 2019;12(6):1079-1091.

    OpenUrlCrossRef
28. 28.↵
    Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
29. 29.↵
    1. Marx A,
    2. Backes C,
    3. Meese E,
    4. Lenhof HP,
    5. Keller A

    . EDISON-WMW: Exact dynamic programing solution of the Wilcoxon-Mann-Whitney test. Genomics Proteomics Bioinformatics 2016;14(1):55-61.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Weber DJ,
    2. Gergen MF,
    3. Sickbert-Bennett EE,
    4. Short KA,
    5. Lanza-Kaduce KE,
    6. Rutala WA

    . Frequency of contamination of single-patient-use nebulizers over time. Infect Control Hosp Epidemiol 2014;35(12):1543-1546.

    OpenUrl